|16 March 2016|
Inovio Pharmaceuticals announced the collaboration deal today with the Wistar Institute for preventive and therapeutic DNA-based immunotherapy applications and products for cancers and infectious diseases developed by David B Weiner, Ph.D., and his Wistar laboratory.
“This new agreement with Wistar starts a whole new chapter of Inovio’s R&D leadership in one of the most important emerging medical technologies: DNA-based immunotherapies. We congratulate Dr Weiner with respect to his multiple new roles at Wistar and the significantly expanded lab and resources available to him to continue pursuing his life’s passion. We look forward to a long and fruitful relationship with this eminent institution to continue advancing cutting edge DNA-based immunotherapies and DNA-based monoclonal antibody technology,” said Dr Joseph Kim, Inovio’s President and CEO.